April 2, 2024 7:25am

The oversold have needs though economic and market worries rob us of buying willpower?

News: Verve Therapeutics (VERV -$3.60 or -28.15% pre -open) has paused enrollment for an early-stage study testing its experimental gene editing therapy for high cholesterol after a patient experienced a severe drug-related adverse event.

Pre-open Indicators: 3 Sell into Strength, 1 Positive and 4 Negative Indicators

Subscription is coming; a “buck” a day will keep your portfolio in play - be a subscriber to continue reading! Join me … in the NO spin zone and new website!

Never leave an investor uninformed!

 

Remember that overnight and pre-open actions’ futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

Framing the main takeaway … pricing, volume and volatility!

My version of the morning’s numbers is written to be informative; it’s including what happened or will beyond the headline and shapes today’s markets as seen by RMi.

 

Tuesday: The pre-open Dow futures are DOWN -0.36% or (-145 points), the S&P futures are DOWN -0.23% or (-12 points) as the Nasdaq futures are DOWN -0.32% or (-59 points)

Stock futures are down and slipped Tuesday,

European stocks turned flat,

Asia pacific market were mixed.

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Monday, the Dow closed DOWN -240.52 points or -0.60%, the S&P closed DOWN -10.58 points -0.20% while the Nasdaq closed UP +17.37 points or +0.11%

Economic Data Docket: JOLTS Job Openings, February (8.87 million previously); Factory Orders, February (1.0% expected, -3.6% previously); Durable Goods Orders, February final (+1.4% previously)

 

Monday’s night RegMed Investors (RMi) Closing Bell: “An early share pricing eclipse in first session of April? No need for smoked glasses as earnings season is all but over after share pricing weaknesses highlighted Q1/24.” … https://www.regmedinvestors.com/articles/13398

 

Q1/24: Q2:

 April - 1 negative close

Q1/24:

  • March – 8 positive and 12 negative closes
  • February – 1 market holiday, 11 positive and 9 negative closes
  • January: 2 holidays, 11 negative and 8 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Sell into Strength:

Monday. Friday was holiday, Thursday, Wednesday, Tuesday and Monday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Alnylam Pharmaceuticals (ALNY) closed up +$3.88 after Thursday’s -$4.94 after Wednesday’s +$2.42 with a positive +$1.67 or -1.09% pre-open indication. pre-open indication.

Blueprint Medicine (BPMC) closed up +$1.56 after Thursday’s +$5.12 with a neutral pre-open indication.

Generation Bio (GBIO) closed up +$0.22 after Thursday’s +$0.37 with neutral pre-open indication.

 

Negative Indication:

Monday. Friday was holiday, Thursday, Wednesday, Tuesday and Monday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Adverum Biotechnologies (ADVM) closed down -$0.69 after Thursday’s -$0.52 with a neutral pre-open indication.

Beam Therapeutics (BEAM) closed down -$0.38 after Thursday’s -$0.92 with a negative -$0.11 or -0.34% pre-open indication

Prime Medicine (PRME) closed down -$0.24 after Thursday’s +$0.24 with a neutral pre-open indication.

Verve Therapeutics (VERV) closed down -$0.49 after Thursday’s +$0.09 with a negative -$3.60 or –28.15% pre-open indication

 

Positive Indications:

Monday, Friday was holiday, Thursday, Wednesday, Tuesday, Monday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Maintaining, Solid Biosciences (SLDB) closed down -$0.88 after Thursday’s-$0.93 and Wednesday’s +$0.68 with a neutral pre-open indication.

 

The BOTTOM LINE: Feeling nervous and cautious this Tuesday a.m.!

Yesterday 4/1, the Nasdaq climbed in the final minutes to post a +0.1% gain

  • After European markets were closed on Monday and most markets across the globe were closed on Friday.
  • Benchmark 10-year and two-year Treasury yields jumped to two-week peaks following the manufacturing data.
  • The U.S. monthly jobs report is due on Friday.

Presenting alternative hypotheses clarifies material facts and evidence available to investors.

  • While many talk about the shift in alternating sentiment, I monitor the pulse and focus of possible outcomes.
  • Skim if you can trim, buy if it will fly and sell if compelled!

 

I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

A bit preachy, “The take-away, don’t dwell on what’s happened and follow RMi’s lesson of investing in those who guide and then meet short-term expectation.”

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.